Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented different innovative pricing and reimbursement models. In an article for MedTech Strategist, we explore whether similar innovative reimbursement and contracting schemes might be developed for medical technologies and how the challenges they bring might be overcome.
Assessment of the impact of earlier access to disease-modifying treatments with more convenient administration frequency in reducing the socioeconomic burden for multiple sclerosis patients in Europe
The socioeconomic impact of Multiple Sclerosis (MS) extends to various areas of a patient’s life including personal wellbeing and mental health, family life...